RecruitingRecruiting
Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
NCT07516769 · Tanta University
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Clinical Study Evaluating the Effect of Nicorandil as Anti-inflammatory and Immune Modulatory in Patients With Rheumatoid Arthritis
About this study
This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
Eligibility criteria
Inclusion Criteria:
* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) \>2.6.
* Patients receiving the conventional DMARDs
Exclusion Criteria:
* Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.
* Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.
* Patients receiving oral prednisolone greater than 15mg/day.
* Patients with hypersensitivity to study medications.
* Patients using antioxidants.
* Pregnant and lactating females.
Study design
Enrollment target: 46 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-11-01
Estimated completion: 2027-04
Last updated: 2026-06-18
Interventions
Drug: Nicorandil 5 MG Oral Tablet
Primary outcomes
- • change in 28-joint count Disease Activity Score (DAS28) using C- reactive protein level (CRP) (3 months)
- • change in Multidimensional Health Assessment Questionnaire (MDHAQ) scores. (3 months)
Sponsor
Tanta University · other
Contacts & investigators
ContactKarim Abu Elfath Hussein · contact · Kareem_hussein@pharm.tanta.edu.eg · +201141332986
All locations (1)
Tanta universityRecruiting
Tanta, Gharbia Governorate, Egypt